- Sorrento Therapeutics (NASDAQ:SRNE) climbs 4.5% after signing a licensing pact with Columbia University for the rights to a rapid one-step diagnostic test that detects SARS-CoV-2 virus in as little as 30 minutes from a saliva sample.
- The test developed by Columbia's team, to be marketed by Sorrento under the COVI-TRACE name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point-of-care, on-site, or potentially at-home testing.
- Previously: Sorrento to acquire COVID-19 therapy developer (July 24)
Sorrento jumps 4.5% after licensing rapid COVID-19 test from Columbia
Recommended For You
About SRNEQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRNEQ | - | - |
Sorrento Therapeutics, Inc. |